Nocardia keratitis: clinical course and effect of corticosteroids

Am J Ophthalmol. 2012 Dec;154(6):934-939.e1. doi: 10.1016/j.ajo.2012.06.001. Epub 2012 Sep 5.

Abstract

Purpose: To compare the clinical course of Nocardia species keratitis with keratitis resulting from other bacterial organisms and to assess the effect of corticosteroids as adjunctive therapy using data collected from the Steroids for Corneal Ulcers Trial.

Design: Subgroup analysis of a randomized controlled trial.

Methods: setting: Multicenter randomized controlled trial. study population: Five hundred patients with bacterial keratitis randomized 1:1 to topical corticosteroid or placebo who had received at least 48 hours of topical moxifloxacin. intervention/observation procedure: Topical prednisolone phosphate 1% or placebo and clinical course of Nocardia keratitis. main outcome measures: Best spectacle-corrected visual acuity and infiltrate or scar size at 3 months from enrollment.

Results: Of 500 patients enrolled in the trial, 55 (11%) had a Nocardia corneal ulcer. Patients with Nocardia ulcers had better presentation visual acuity compared with non-Nocardia ulcers (median Snellen visual acuity, 20/45, compared with 20/145; P < .001) and comparable 3-month visual acuity (median, 20/25, vs 20/40; P = .25). Nocardia ulcers had approximately 2 lines less of improvement in visual acuity compared with non-Nocardia ulcers (0.21 logarithm of the minimal angle of resolution; 95% confidence interval, 0.09 to 0.33 logarithm of the minimal angle of resolution; P = .001). This difference may reflect the better starting visual acuity in patients with Nocardia ulcers. In Nocardia ulcers, corticosteroids were associated with an average 0.4-mm increase in 3-month infiltrate or scar size (95% confidence interval, 0.03 to 0.77 mm; P = .03).

Conclusions: Nocardia ulcers responded well to treatment. They showed less overall improvement in visual acuity than non-Nocardia ulcers, but had better presentation acuity. Corticosteroids may be associated with worse outcomes.

Trial registration: ClinicalTrials.gov NCT00324168.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / therapeutic use*
  • Aza Compounds / administration & dosage
  • Aza Compounds / therapeutic use
  • Corneal Ulcer / diagnosis
  • Corneal Ulcer / drug therapy*
  • Corneal Ulcer / microbiology
  • Double-Blind Method
  • Eye Infections, Bacterial / diagnosis
  • Eye Infections, Bacterial / drug therapy*
  • Eye Infections, Bacterial / microbiology
  • Female
  • Fluoroquinolones
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Moxifloxacin
  • Nocardia / genetics
  • Nocardia / isolation & purification*
  • Nocardia Infections / diagnosis
  • Nocardia Infections / drug therapy*
  • Nocardia Infections / microbiology
  • Polymerase Chain Reaction
  • Prednisolone / administration & dosage
  • Prednisolone / analogs & derivatives
  • Prednisolone / therapeutic use
  • Quinolines / administration & dosage
  • Quinolines / therapeutic use
  • Treatment Outcome
  • Visual Acuity / physiology

Substances

  • Anti-Infective Agents
  • Aza Compounds
  • Fluoroquinolones
  • Glucocorticoids
  • Quinolines
  • prednisolone phosphate
  • Prednisolone
  • Moxifloxacin

Associated data

  • ClinicalTrials.gov/NCT00324168